SPYRE THERAPEUTICS INC (SYRE:NASDAQ)
$73.65 -0.4 (-0.5402%)
Analysed SPYRE THERAPEUTICS INC (SYRE:NASDAQ) News Sources
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers
27-04-2026
yahoo.com
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
30-04-2026
yahoo.com
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise
01-05-2026
yahoo.com
Spyre Therapeutics Announces Grants of Inducement Awards
01-05-2026
yahoo.com
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
05-05-2026
yahoo.com
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
05-05-2026
yahoo.com
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
17-05-2026
fool.com
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
17-05-2026
fool.com
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
17-05-2026
fool.com
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
17-05-2026
fool.com
What is the current price of SPYRE THERAPEUTICS INC (SYRE:NASDAQ)?
The current price of SPYRE THERAPEUTICS INC (SYRE:NASDAQ) is $73.65.
SPYRE THERAPEUTICS INC (SYRE:NASDAQ) absolute price change since previous trading day?
The absolute price change of SPYRE THERAPEUTICS INC (SYRE:NASDAQ) since the previous trading day is $-0.4.
SPYRE THERAPEUTICS INC (SYRE:NASDAQ) percentage price change since previous trading day?
The percentage price change of SPYRE THERAPEUTICS INC (SYRE:NASDAQ) since the previous trading day is -0.5402%.
What is the most recent average sentiment score for SPYRE THERAPEUTICS INC (SYRE:NASDAQ)?
The most recent average sentiment score for SPYRE THERAPEUTICS INC (SYRE:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for SPYRE THERAPEUTICS INC (SYRE:NASDAQ)?
The most recent sentiment for SPYRE THERAPEUTICS INC (SYRE:NASDAQ) is .
SEC-8K** Filing Available For SPYRE THERAPEUTICS INC (SYRE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.